Recursion Pharmaceuticals Inc (RXRX) showcases strong financial management and strategic partnerships while navigating challenges in drug discovery.

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to ...

The pro-forma consolidated turnover reached over RON 3.17 billion (approximately EUR 630 million), up by almost 17% compared ...

Day One Biopharmaceuticals, Inc. is rated Buy with net product revenues of $52.8M, up 36% from the prior quarter. Read more ...

Delivered 41% revenue growth and 83% gross margin in Q4 2025;Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 ...

HNI Corporation (NYSE:HNI) has completed its acquisition of Steelcase, combining two established brands in workplace ...

As university sources told the Register over a month ago, the Holy Cross priest was “blindsided” by the appointment of the outspoken abortion advocate to the leadership position, which had been signed ...

Rising costs are pushing Trafalgar town leaders to weigh a water rate increase they say is necessary for sustainability.

Biodesix expects to deliver $106 million to $112 million in annual revenue for 2026, representing 23% growth at the midpoint over 2025. The guidance includes consideration of recent weather events and ...

The massive growth at Celsius is a reflection of its $1.8 billion acquisition of Alani Nu LLC in April and its expanded partnership with PepsiCo in September, which included the integration of its ...